• Site Search
  • News
  • Product
  • Zhejiang Medical Technology Development Co., Ltd.

    2020 year
    27 day
    Winhealth Pharma Participated in the 2nd Healthy China Innovation Communication Conference ...


    Winhealth Pharma Participated in the 2nd Healthy China Innovation Communication Conference and the 7th China Medical Brand Building Conference

    From Sept. 25th to 26th, 2020, the 2nd Healthy China Innovation Communication Conference and the 7th China Medical Brand Building Conference, sponsored by the Chinese Medical Doctor Association, the Health Communication Working Committee of the Chinese Medical Doctor Association, the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration, and the Affiliated Hospital of Nantong University, was held in a grand way in Hainan Boao Forum International Conference Center. Winhealth Pharma Group ((hereinafter referred to as Winhealth Pharma) and its subsidiary Bo’ao Winhealth Rare Disease Medical Center jointly participated as exhibitors.


    The conference is aimed to summarize the practical experience of health communication during the anti-pandemic, enhance the ability of health communication workers to respond to major public health emergencies in health communication and public opinion guidance, and share the Chinese approach with the world.

    At the conference, Li Lanjuan, academician of the Chinese Academy of Engineering and dean of Boao Super Hospital, delivered a keynote speech on 'Scientifically Preventing and Controlling Pandemic and Protecting People's Health', recalling the anti-pandemic process and introducing the important role of combining advanced technology and medicine during the pandemic, and sharing anti- pandemic experience.

    Since the pandemic, Winhealth Pharma has also been committed to epidemic prevention and control. It is believed that with our joint efforts, we will win the battle against the disease.

    As an exhibitor at the conference, Winhealth Pharma elaborately designed the booth and carefully arranged the exhibition to show everyone the outstanding achievements of Winhealth Pharma in promoting the development of China's medical and health industry, and introduced to the participants about its diversified product portfolio and corporate culture construction.

    维健医药参展第二届健康中国创新传播大会暨第七届中国医疗品牌建设大会 维健医药参展第二届健康中国创新传播大会暨第七届中国医疗品牌建设大会

    Meanwhile, via the exhibition Bo’ao Winhealth Rare Disease Medical Center invested and established by Winhealth Investment (Hong Kong) Co., Ltd was introduced to the participants. During the exhibition, the staff also patiently explained relevant information about the Boao Lecheng Winhealth Pharma Rare Disease Clinical Medicine Center for the attendees, and provided promotional materials, coffee breaks and other items to help facilitate the success of the conference.

    Finally, this exhibition event came to a successful end. In the future, we will continue to innovate cooperation models, explore wider prospects for global cooperation, and work together to maintain life and health and benefit hundreds of millions of patients.


    BO’AO WINHEALTH RARE DISEASE MEDICAL CENTER/BO’AO RARE DISEASE MEDICAL CENTER was jointly established on April 10, 2020 in BO’AO Lecheng international medical tourism pilot zone in the province of Hainan in China, by Win Health Investment (HK) Limited., Le Cheng Administration, Ruida Medicell International Medical Center.


    Our mission is to keep pace with the latest development of the world to introduce the most advanced rare disease medical products into Chinese market, bringing unprecedented hope to patients with rare disease in China and neighboring countries and regions. We are committed to establishing the most comprehensive and advanced rare disease clinical medical center with the most advanced diagnosis and treatment services in China, Southeast Asia and other surrounding areas.

    About Winhealth Pharma


    Hong Kong Winhealth Pharma Group is an innovative Hong Kong-headquartered and China-focused pharmaceutical company, is committed to filling the huge medical demand gap of Greater China market by introducing and commercializing the patents and owns Established Pharmaceutical Division (EPD) and rare diseases-orientated Innovative Therapeutics Division (ITD). The former covers brand-name drugs in five fields: respiratory diseases and anti-infection, cardiovascular diseases, digestion and liver diseases, dermatology and cosmetic medicine, and urinary system diseases. Winhealth Pharma provides integrated service of local research and development, registration and commercialization for the internationally renowned pharmaceutical enterprises, and has become one of well-known CDCOs (contract development and commercialization organizations) in China, and the clients include several transnational pharmaceutical enterprises listed in the world’s top 500 enterprises. Headquartered in Hong Kong, Winhealth Pharma also establishes the operating centers and offices in Hangzhou, Shanghai, Beijing, Guangzhou, Hainan, Tokyo and Munich. Visit for more information.

    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline )
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.